This trial is designed to evaluate the tolerability and potential efficacy of tyrosine kinase inhibitors in patients with mild cognitive impairment or dementia. Baseline and outcome measures utilize validated tests that are appropriate for repeated measures. The study population is sufficiently broad and the conditions of interest are sufficiently prevalent so that recruitment of the projected numbers of subjects is not a limiting factor.